These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 3519041)

  • 1. The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy: a prospective, randomized, double-blind trial.
    Joss RA; Galeazzi RL; Bischoff AK; Pirovino M; Ryssel HJ; Brunner KW
    Clin Pharmacol Ther; 1986 Jun; 39(6):619-24. PubMed ID: 3519041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective randomized double-blind crossover study comparing the antiemetic activity of alizapride and metoclopramide in patients receiving cisplatin chemotherapy.
    Basurto C; Roila F; Del Favero A; Ballatori E; Minotti V; Tonato M
    Cancer Invest; 1988; 6(5):475-9. PubMed ID: 3063335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-emetic effect of high-dose metoclopramide vs alizapride--a randomised crossover study.
    Seng KT; Tiong CE; Hiang TC
    Br J Clin Pharmacol; 1994 Sep; 38(3):282-4. PubMed ID: 7826833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Control of the emesis induced by cisplatin in patients with head and neck neoplasms. Randomized study of metoclopramide alizapride and placebo].
    Denaro A; Rossi M; Garozzo A; Matera M; Neri V
    G Ital Oncol; 1990; 10(1-2):29-34. PubMed ID: 2192985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting.
    Gralla RJ; Itri LM; Pisko SE; Squillante AE; Kelsen DP; Braun DW; Bordin LA; Braun TJ; Young CW
    N Engl J Med; 1981 Oct; 305(16):905-9. PubMed ID: 7024807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alizapride, a new substituted benzamide, as an antiemetic during cancer chemotherapy.
    Joss RA; Galeazzi RL; Bischoff AK; Brunner KW
    Eur J Clin Pharmacol; 1985; 27(6):721-5. PubMed ID: 3987777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Phase I study of alizapride in cancer patients treated with cisplatin].
    Nicaise C; Rozencweig M; Ortmans M; Frisque C; Bleiberg H
    Sem Hop; 1983 Sep; 59(31):2161-5. PubMed ID: 6312589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The antiemetic activity of high-dose metoclopramide and high-dose alizapride in combination with lorazepam in patients receiving cancer chemotherapy. A prospective, randomized, double-blind study.
    Molino A; Guglielmo L; Azzolini ME; Biondani P; Capelli MC; Grandinetti A; Griso C; Martinelli G; Martini N; Zanotti R
    Oncology; 1991; 48(2):111-5. PubMed ID: 1997932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fractionated chemotherapy--granisetron or conventional antiemetics? The Granisetron Study Group.
    Diehl V
    Eur J Cancer; 1992; 28A Suppl 1():S21-8. PubMed ID: 1320916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose alizapride versus high-dose domperidone: a double-blind comparative study in the management of cis-platinum-induced emesis.
    Huys J; Troch M; Bourguignon RP; Smets P
    Curr Med Res Opin; 1985; 9(6):400-6. PubMed ID: 3886305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized crossover antiemetic study in cisplatin-treated patients. Comparison between high-dose i.v. metoclopramide and high-dose i.v. dexamethasone.
    Frustaci S; Grattoni E; Tumolo S; Crivellari D; Figoli F; Galligioni E; Veronesi A; Tirelli U; Grigoletto E
    Cancer Chemother Pharmacol; 1986; 17(1):75-9. PubMed ID: 3698180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Droperidol, alizapride and metoclopramide in the prevention and treatment of post-operative emetic sequelae.
    Kauste A; Tuominen M; Heikkinen H; Gordin A; Korttila K
    Eur J Anaesthesiol; 1986 Jan; 3(1):1-9. PubMed ID: 3780685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of a new antiemetic agent: alizapride. A randomized double-blind crossover controlled trial.
    Bleiberg H; Gerard B; Dalesio O; Crespeigne N; Rozencweig M
    Cancer Chemother Pharmacol; 1988; 22(4):316-20. PubMed ID: 3048762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
    Bonneterre J; Chevallier B; Metz R; Fargeot P; Pujade-Lauraine E; Spielmann M; Tubiana-Hulin M; Paes D; Bons J
    J Clin Oncol; 1990 Jun; 8(6):1063-9. PubMed ID: 2140854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective, randomized double-blind trial comparing metoclopramide alone with metoclopramide plus dexamethasone in preventing emesis induced by high-dose cisplatin.
    Parikh PM; Charak BS; Banavali SD; Koppikar SB; Giri N; Nadkarni P; Saikia TK; Gopal R; Advani SH
    Cancer; 1988 Nov; 62(10):2263-6. PubMed ID: 3052785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effects of intravenously administered alizapride and prochlorperazine in cisplatin-induced emesis.
    Roché H; Hyman G; Nahas G; Stoopler M; Ellison R; Desjardins R
    Cancer Invest; 1987; 5(2):89-93. PubMed ID: 3607576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alizapride alone or alizapride-dexamethasone compared with metoclopramide-dexamethasone in patients at high risk of acute emesis after cisplatin. A randomized cross-over study.
    Pollera CF; Nardi M; Marolla P; Calabresi F
    Acta Oncol; 1991; 30(6):725-9. PubMed ID: 1958393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of administration rate on cisplatin-induced emesis.
    Jordan NS; Schauer PK; Schauer A; Nightingale C; Golub G; Martin RS; Williams HM
    J Clin Oncol; 1985 Apr; 3(4):559-61. PubMed ID: 3884747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Alizapride in a double-blind trial with metoclopramide in nausea and vomiting caused by radiotherapy].
    Budach V; Krüger K
    Fortschr Med; 1983 Oct; 101(39):1792-4. PubMed ID: 6642386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy.
    Sledge GW; Einhorn L; Nagy C; House K
    Cancer; 1992 Nov; 70(10):2524-8. PubMed ID: 1423181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.